Article
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
Molecular oncology - 1 Jun 2024
Maione Federica, Oddo Daniele, Galvagno Federica, Falcomatà Chiara, Pandini Marta, Macagno Marco, Pessei Valeria, Barault Ludovic, Gigliotti Chiara, Mira Alessia, Corti Giorgio, Lamba Simona, Riganti Chiara, Castella Barbara, Massaia Massimo, Rad Roland, Saur Dieter, Bardelli Alberto, Di Nicolantonio Federica
Abstract excerpt
Serine/threonine-protein kinase B-raf (BRAF) mutations are found in 8-15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF-mutant human cells display a high rate of protein production, causing proteotoxic stress, and are selectively sensitive to the proteasome inhibitors bortezomib and carfilzomib. In this work, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.